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Short-Term Restaging of Patients with Non-small Cell Lung
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Bradley Sabloff, MD,* and Reginald Munden, MD*
Objective: To determine whether computed tomography (CT) per-
formed within a month of receiving chemotherapy is useful in
assessing response among patients with non-small cell lung cancer
(NSCLC).
Patients and Methods: Consecutive patients receiving chemother-
apy for NSCLC who underwent short-term CT restaging between
April 2001 and June 2005 were included in the study. Serial CT
scans were performed within 31 days (mean, 24 days; range, 9-31
days) after receiving chemotherapy for all patients. Tumors were
measured in consensus by two diagnostic radiologists. Tumor re-
sponse was assessed using uni-dimensional tumor measurements
according to Response Evaluation Criteria in Solid Tumors criteria.
Results: There were 57 patients in the study (30 men, 27 women;
mean age, 63 years; age range, 37–85 years). Tumor histology
included adenocarcinoma (n  30), squamous cell carcinoma (n 
17), and NSCLC otherwise unspecified (n  10). Clinical tumor,
node, metastasis stage was stage II (n  2), stage III (n  11), and
stage IV (n  44). A significant change in tumor size was observed
in eight patients (14%), with tumor regression in two (3%) and
progression in six (11%). For these patients, CT scans were per-
formed within 31 days (mean, 25 days; range, 17-31 days). Among
the six patients with tumor progression, early detection of therapeu-
tic failure resulted in a change or a discontinuation of chemotherapy
for five.
Conclusion: Early restaging CT is useful in evaluating therapeutic
response among patients with NSCLC and may allow the institution
of more appropriate therapy.
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Lung cancer is the leading cause of cancer-related deaths inboth men and women in the United States and commonly
presents with advanced disease.1 Chemotherapy has been
shown to increase the 5-year survival rate among patients
with non-small cell lung cancer when added to surgery or
radiation for patients who have local or regional disease.2–9 In
advanced disease, as a single modality, chemotherapy pro-
longs survival and improves quality of life as first- and
second-line therapy.7–9 However, after the initiation of che-
motherapy, tumor progression can occur in up to one third of
patients.10 Early determination of this therapeutic failure is
important in patient management and assists clinical deci-
sions concerning discontinuation of ineffective treatment and
institution of alternative therapy. However, the prevailing
standard assessment of therapeutic response often precludes
an early prediction of tumor response. In this regard, tumor
response is usually determined using World Health Organi-
zation (WHO)11 or Response Evaluation Criteria in Solid
Tumors (RECIST)12 criteria and is typically based on com-
puted tomographic (CT) imaging with serial measurements of
tumor size performed at 6- to 8-week intervals. The objective
of this study was to assess whether changes in tumor size
measured on serial CT scans performed earlier than the
standard convention would allow an assessment of therapeu-
tic response among patients with non-small cell lung cancer
(NSCLC).
PATIENTS AND METHODS
We performed a retrospective review of CT scans from
consecutive patients with NSCLC receiving chemotherapy at
our institution between April 2001 and June 2005. Patients
were eligible for inclusion into the study if they were receiv-
ing chemotherapy for histologically proven primary NSCLC
and if they had undergone early restaging CT imaging of the
chest at an interval of no longer than 31 days at least once
while on treatment. We recorded demographic characteris-
tics, tumor histology, tumor stage and grade, chemotherapy,
and subsequent follow-up. The study was approved by our
Institutional Review Board.
All CT scans were performed on a helical (GE Hi-
Speed, GE Healthcare, Milwaukee, WI) or multi-slice CT
scanner (GE Lightspeed, GE Healthcare), with a collimation
of 7-mm (single-slice helical scans) or between 1.25 and
2.5-mm (multi-slice scans). Axial images were reconstructed
with a slice thickness of 1.25 to 7 mm. All scans were
performed with IV contrast (300 mg/dL non-ionic iodinated
contrast, injected at 3–4 mL/s). For each patient, the initial
CT scan (scan 1) and the follow-up scan performed less than
31 days later (scan 2) were reviewed on a dedicated work-
station (iSite; Stentor Inc, Brisbane, CA) by two chest radi-
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ologists who interpreted the scans together. All images were
reviewed in both mediastinal soft tissue windows (center,
55; width, 500) and parenchymal lung windows (center,
600; width, 1500).
Tumor measurements were made on two serial CT
scans performed at an interval of less than or equal to 31 days
(scan 1 and scan 2) that had been requested for restaging
purposes while the patient was receiving chemotherapy for
the treatment of NSCLC. On each scan, tumor measurements
were performed in consensus by two radiologists at a joint
interpretation session using electronic calipers and according
to RECIST criteria.12 Up to 10 tumor targets were identified
on each scan (with a maximum of five in each organ) and
measured along their longest axial diameter, and the sum of
these measurements was recorded for each patient. Tumor
measurements were performed using either soft tissue or lung
window settings, according to the anatomical location of the
tumor target and the visibility of the lesion: nodules or masses
abutting the mediastinum or chest wall were measured on
mediastinal soft tissue windows to accurately delineate them
from normal adjacent soft tissue, whereas lesions surrounded
entirely by lung parenchyma were measured on lung win-
dows. The same window setting was used for both scans
(scans 1 and 2) for each patient. Patients were excluded from
the study if the tumor targets were not measurable, if the
largest tumor target was smaller than 10 mm in diameter, or
if the tumor was obscured by surrounding atelectasis or
consolidation. Total tumor size was determined by calculat-
ing the sum of the measurements of the longest axial diam-
eters of each of the tumor targets, according to RECIST
criteria. Significant tumor progression and regression were
defined by an overall increase of at least 20% or decrease of
at least 30% in the total tumor size, respectively. A change in
total tumor size of less than this was defined as stable disease.
Statistical Analysis
Results were documented using descriptive analyses of
frequencies, means, and medians. Differences between pa-
tients who showed a significant change in tumor size (pro-
gression or partial response) and patients with stable disease
were analyzed using Fisher’s exact test.
RESULTS
A total of 57 patients with NSCLC who were receiving
chemotherapy were eligible for inclusion in the study (30
men, 27 women; mean age, 63 years; age range, 37–85
years). Table 1 summarizes the characteristics of the patients,
tumor histology, grade, stage, and treatment. Most patients (n
 42, 74%) had metastatic disease at the time of serial CT
scanning and were undergoing definitive chemotherapy. The
remaining patients (n  15, 26%) were receiving induction
neoadjuvant therapy before anticipated surgical resection.
Total tumor size at baseline (scan 1) as measured by RECIST
criteria ranged between 1.1 and 30.9 cm (mean, 7.3 cm).
The mean time interval between serial CT scans (scans
1 and 2) for each patient was 24 days (median, 24 days;
range, 9–31 days). Indications for early follow-up CT scans
included: routine restaging after chemotherapy (n  39),
suspected pulmonary embolism (n  4), unexplained dys-
pnea (n  4), suspected pneumonia (n  3), investigation of
abnormalities on chest radiographs (n  2), shoulder-tip pain
(n 1), abdominal pain (n 1), lethargy (n 1), evaluation
of a pleural effusion (n  1), and in the course of assessment
of hematuria (n  1). Eight patients had suspected tumor
progression either on clinical grounds (n  6) or because of
chest radiograph abnormalities (n 2); there were no specific
signs suggestive of disease progression among the remaining
49 patients.
The frequency and magnitude of tumor response or
progression during this time interval was assessed for each
patient (Table 2). A total of eight patients (14%) demon-
strated significant interval changes in total tumor size during
the time period between the two CT scans. Among these
patients, CT scans were performed between 17 and 31 days
(mean, 25 days). In two patients with metastatic adenocarci-
noma, tumor size decreased by more than 30% (mean, 36%;
range, 32–40%) over a period of 20 to 24 days (mean, 22
days) (Fig. 1), allowing chemotherapy to be continued with
greater confidence. In the six other patients, significant in-
creases in tumor size were measured (mean, 26%; range,
21–33%), occurring over periods of 17 days to 31 days
(mean, 26 days) (Figs. 2 and 3). The histology of these
tumors was adenocarcinoma (n  3), squamous cell carci-
noma (n  2), and NSCLC not otherwise specified (n  1).
For four of these patients (two with adenocarcinoma, two
with squamous cell carcinoma), histology demonstrated
TABLE 1. Patient and tumor characteristics
Patient characteristics
Age (yr) 63 (37–85)
Sex 30 men, 27 women
Scan interval (days) 24 (9–31)
Tumor pathology
Adenocarcinoma 30 (52.5)
Squamous cell carcinoma 17 (30)
NSLC (NOS*) 10 (17.5)
Tumor stage
Stage I 0
Stage II 2 (4)
Stage III 11 (19)
Stage IV 44 (77)
Current chemotherapy
First-line 23 (40)
Second-line 10 (18)
More than second-line 24 (42)
Chemotherapy type
Platinum-based 18 (31)
Single-agent tyrosine kinase inhibitor 16 (28)
Combination tyrosine kinase inhibitor 6 (11)
Other 17 (30)
Total tumor size on first CT scan (cm)
Mean 7.3
Median 6.2
Range 1.1-30.9
Values are n (%) or mean (range). NOS, not otherwise specified; NSCLC,
non-small cell lung cancer; CT, computed tomography.
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poorly differentiated tumors. For five of these patients, che-
motherapy was discontinued (n 4) or changed to a different
regimen (n  1) as a result of the CT findings. The sixth
patient died shortly after scan 2 as a result of disease pro-
gression.
Table 3 summarizes the changes in tumor size accord-
ing to patient, tumor, and treatment characteristics. Tumor
progression at short-term follow-up was observed only
among patients with metastatic disease (n  6, 14%), but the
difference was not statistically significant when compared
with patients without metastases (p  0.3, Fisher’s exact
test). Similarly, tumor progression at short-term follow-up
did not vary significantly with respect to first-line chemother-
apy versus second-line or more chemotherapy (p  0.4).
DISCUSSION
Therapeutic response to chemotherapy among patients
with NSCLC can be determined clinically, biochemically, or
by surgical pathologic restaging or image-based serial mea-
surements of tumor size.12,13 Because tumor measurements
before and after chemotherapy are usually considered pref-
erable in the determination of therapeutic effectiveness, pa-
tients are typically evaluated using serial CT scans. Based on
growth rates/doubling times of NSCLC, it is generally ac-
cepted that CT is of limited use in the early assessment of
therapeutic response among patients with NSCLC treated
with chemotherapy. Consequently, CT is typically performed
at intervals of 6 weeks to 2 months in most current protocols,
a time period that corresponds to an assessment of therapeutic
response after at least two cycles of conventional chemother-
apy. However, earlier detection of tumor growth in patients
with tumors that are resistant to chemotherapy is of potential
benefit because it allows the timely discontinuation or change
of chemotherapy regimens that are ineffective and can help to
avoid a delay in the administration of potentially effective
second- or third-line chemotherapy agents.
Conventional restaging methods using CT scanning
depend on anatomical changes in tumor size. However, ac-
curate determination of response may require functional and
molecular techniques that assess metabolism, growth kinet-
ics, angiogenesis growth factors, tumor cell markers, and in
vivo genetic alterations and gene expression.14 Recently,
positron emission tomography (PET) imaging using the glu-
cose analogue [18F]-fluoro-2-deoxy-D-glucose (FDG), has
been advocated as an alternative to anatomic imaging in the
assessment of therapeutic response. It has been reported that
FDG-PET imaging can be used to determine therapeutic
response earlier and more accurately than CT.15–18 However,
a poor understanding of the underlying cellular mechanisms,
absence of consensus concerning optimal time to image for
TABLE 2. Tumor response during short-term follow-up
interval
Change in total tumor size
Patients
(n  57)
Magnitude of tumor
response (%)
Partial response
30% reduction in size 2 (3) 36 (32-40)
Stable disease
20 – 30% reduction in size 1 (2) 28
10 – 19% reduction in size 6 (11) 13 (10-18)
10% change in size 34 (59) 2 (-9–6)
10 – 20% increase in size 8 (14) 13 (10-15)
Tumor progression
 20% increase in size 6 (11) 26 (21-33)
Values are n(%) or n(range).
FIGURE 1. The patient was a 37-year-old man with poorly
differentiated metastatic adenocarcinoma. A, CT image (me-
diastinal windows) before treatment shows necrotic primary
tumor in left upper lobe (arrow). Mass measured 30.1 mm
in longest axis. B, CT image (mediastinal windows) 20 days
after chemotherapy shows significant interval reduction in
size of primary mass (arrow) to 18 mm in longest axis.
FIGURE 2. The patient was an 85-year-old woman with
metastatic adenocarcinoma. A, CT image (mediastinal win-
dow) before treatment shows irregular 6.4-cm soft tissue
mass in the left upper lobe abutting mediastinum. B, CT im-
age 28 days after chemotherapy shows interval enlargement
of mass to 7.5 cm, which now has a larger interface with
the mediastinum.
FIGURE 3. The patient was a 60-year-old man with meta-
static non-small cell lung cancer. A, CT image (mediastinal
windows) shows an 11.2-cm left hilar mass causing marked
compression of the left main pulmonary artery (arrow). B, CT
image (mediastinal windows) 31 days after chemotherapy
shows interval enlargement of primary mass measured at
12.2 cm and causing more marked compression of the left
main pulmonary artery (arrow).
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therapeutic response, and numerous methodological issues
regarding quantification and reproducibility of FDG uptake
have limited its clinical application.19 Additionally, the role
of FDG-PET imaging in the assessment of therapeutic re-
sponse requires further extensive evaluation similar to that
used to validate the RECIST criteria before its routine use in
the assessment of therapeutic response could be considered.
Consequently, CT imaging, which is widely available and
validated in the assessment of therapeutic response, remains
the primary modality used in most clinical trials. However, a
limitation of CT imaging is that the assessment of response to
chemotherapy is not timely and often only allows a re-
evaluation of therapeutic options after two cycles of chemo-
therapy.
The results of our study show that performing serial CT
scans at short intervals can detect changes in tumor size after
only one cycle of chemotherapy (3–4 weeks) and can change
clinical management. In addition to demonstrating significant
tumor regression in two patients (3%), which allowed therapy
to be continued with greater confidence in these patients, six
patients (11%) had significant progression of malignancy,
resulting in discontinuation or change of chemotherapy drugs
earlier than might otherwise have occurred.
Potential limitations of our study include factors inher-
ent to a retrospective review, i.e., the variability in time that
patients received CT imaging after the initiation of therapy
and the diversity in tumor histology of the patients and
chemotherapy regimens received. It is possible that certain
tumor types or chemotherapy regimens are more likely to be
associated with rapid changes in tumor size. Unfortunately, it
was not possible to predict this association from our study
because of the relatively small numbers of patients and the
wide variety of different chemotherapy regimens. A second
limitation is that a conclusion could not reliably be drawn
regarding the relation between tumor response at short-term
follow-up and subsequent tumor behavior in those patients
who demonstrated a non-significant change in size. Eight
patients (14%) demonstrated tumor enlargement that was
considered stable disease according to RECIST criteria (less
than 20%). It is unclear whether the current RECIST defini-
tion of progression is applicable to short-term restaging
scans, and it is possible that this earlier detection of an
increase in tumor size portends a lack of response to therapy.
In fact, chemotherapy was discontinued or changed for five of
these patients. Because it is not clear whether an increase in
size of less than 20% observed on a short-interval restaging
scan can be used to confidently predict subsequent tumor
behavior, a prospective study of the predictive value of
short-interval restaging with CT in a more homogenous group
of patients would be useful.
In conclusion, CT imaging performed earlier than con-
ventional restaging protocols is potentially useful in evaluat-
TABLE 3. Characteristics of patients and tumors according to response
Patients
Characteristic Partial response Stable disease Tumor progression
Patients (n  57) 2 (3) 49 (86) 6 (11)
Age (yr) 58 (37–79) 63 (42–81) 64 (58–69)
Men (n  30) 1 (2) 24 (42) 1 (2)
Women (n  27) 1 (2) 25 (40) 5 (5)
Follow-up interval (days) 22 (20–24) 23 (9–31) 26 (17–31)
Histology
Adenocarcinoma (n  30) 2 (3) 26 (46) 3 (5)
Squamous cell (n  17) 0 15 (26) 2 (3)
NSCLC NOS (n  10) 0 9 (15) 1 (2)
Poorly differentiated (n  19) 1 (2) 15 (26) 4 (7)
Stage
I (n  1) 0 0 0
II (n  2) 0 2 (3) 0
III (n  12) 0 11 (19) 0
IV (n  42) 2 (3) 36 (63) 6 (11)
Chemotherapy
First-line (n  23) 2 (3) 20 (35) 1 (2)
Second-line (n  10) 0 8 (14) 2 (3)
More than second-line (n  24) 0 21 (37) 3 (5)
Chemotherapy type
Platinum-based (n  18) 0 18 (31) 0
Single-agent tyrosine kinase inhibitor (n  16) 1 (2) 14 (25) 1 (2)
Combination tyrosine kinase inhibitor (n  6) 1 (2) 4 (7) 1 (2)
Other (n  17) 13 (23) 4 (7)
Values are n(%) or median (range). NSCLC, non-small cell lung cancer; NOS, not otherwise specified
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ing therapeutic response among patients with NSCLC receiv-
ing chemotherapy. In particular, early restaging CT can
identify tumors refractory to treatment and allow the institu-
tion of more appropriate therapy.
REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J
Clin 2006;56:106–130.
2. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mito-
mycin C, vinblastine and cisplatin) chemotherapy in advanced non-
small-cell lung cancer. Br J Cancer 1995;71:366–370.
3. Arriagada R, Berman B, Dunant A. Cisplatin-based adjuvant chemo-
therapy in patients with completely resected non-small-cell lung cancer.
N Engl J Med 2004;350:3513–3560.
4. Dancey J, Shepherd FA, Gralla RJ. Quality of life assessment of
second-line docetaxel versus best supportive care in patients with non-
small-cell lung cancer previously treated with platinum-based chemo-
therapy: results of a prospective, randomized phase III trial. Lung
Cancer 2004;43:183–194.
5. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of
induction chemotherapy plus high dose radiation versus radiation alone
in stage III non-small cell lung cancer. N Engl J Med 1990;323:940–945.
6. Winton T, Livingston R, Johnson D. Vinorelbine plus cisplatin vs.
observation in resected non-small-cell lung cancer. N Engl J Med
2006;352:2589–2597.
7. Furuse K, Fukuoka M, Kawahara M. Phase III study of concurrent
versus sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small-cell lung
cancer. J Clin Oncol 1999;17:2692–2699.
8. Thongprasert S, Sanguanmitra P, Juthapan W. Relationship between
quality of life and clinical outcomes in advanced non-small cell lung
cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung
Cancer 1999;24:17–24.
9. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosf-
amide, and cisplatin in unresectable non-small-cell lung cancer: effects
on survival and quality of life. J Clin Oncol 1999;17:3188–3194.
10. Sekine I, Tamura T, Kunitoh H, et al. Progressive disease rate as a
surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann
Oncol 1999;10:731–733.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of
cancer treatment. Cancer 1981;47:207–214.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer Inst
2000;92:205–216.
13. Shankar LK, Sullivan DC. Functional imaging in lung cancer. J Clin
Oncol 2006;23:3203–3211.
14. Weissleder R. Molecular imaging: exploring the next frontier. Radiology
1999;212:609–614.
15. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography
in non-small-cell lung cancer: prediction of response to chemotherapy
by quantitative assessment of glucose use. J Clin Oncol 2003;14:2651–
2657.
16. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of
FDG-PET to assess the response in radiation therapy for bronchogenic
carcinoma. Ann Nucl Med 1996;10:193–200.
17. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship
between probability of pathologic tumor control and glucose metabolic
rate measured with FDG PET after preoperative chemoradiotherapy in
locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol
Phys 2002;54:1024–1035.
18. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomog-
raphy is superior to computed tomography scanning for response-
assessment after radical radiotherapy or chemoradiotherapy in patients
with non-small cell lung cancer. J Clin Oncol 2003;21:1285–1292.
19. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission
tomography in prognostic and therapeutic assessment of lung cancer:
systematic review. Lancet Oncol 2004;5:531–540.
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006 Short-Term Restaging of Non-small Cell Lung Cancer
Copyright © 2006 by the International Association for the Study of Lung Cancer 429
